<p>2025 年 4 月 23 日- 上午 8:05</p>
<p>圣地亚哥，2025 年 4 月 23 日（GLOBE NEWSWIRE）-- Organovo Holdings, Inc.（纳斯达克：ONVO）（“公司”）宣布将继续推进其 3D 生物打印和传统技术，作为 VivoSim Labs, Inc.。</p>
<p>公司名称变更为 VivoSim Labs, Inc.将于 2025 年 4 月 24 日生效，公司普通股将于 2025 年 4 月 24 日市场开盘时在纳斯达克资本市场以新股票代码 “VIVS” 开始交易。</p>
<p>现有股东无需对名称和股票代码的变更采取任何行动。公司的普通股将继续在纳斯达克资本市场上市，分配给公司普通股的 CUSIP 号码（68620A302）将保持不变。</p>
<p><strong>前瞻性声明</strong></p>
<p><em>本新闻稿中包含的任何不描述历史事实的声明构成前瞻性声明，符合 1995 年《私人证券诉讼改革法》的定义。此处包含的任何前瞻性声明均基于当前预期，但受到多种风险和不确定性的影响。这些风险和不确定性以及其他因素在公司向 SEC 提交的文件中有更详细的说明，包括其于 2024 年 5 月 31 日提交的 10-K 表格年度报告，以及其于 2025 年 2 月 19 日提交的最新季度报告 10-Q 表格中更新的风险因素。您不应对这些前瞻性声明过度依赖，这些声明仅在作出之日有效。这些警示声明应与公司未来可能发布的任何书面或口头前瞻性声明一起考虑。除非适用法律要求，包括美国的证券法，公司不打算更新任何前瞻性声明，以使这些声明与实际结果、后续事件或情况相符，或反映意外事件的发生。</em></p>
<p><strong>联系方式：</strong></p>
<p>IR@organovo.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRek56QTVPU00yT1RBd01ERTNJekl3TWpBd09EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRek56QTVPU00yT1RBd01ERTNJekl3TWpBd09EVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDRhNjEyZjctMmI3Yi00M2NjLTkyZDEtYzBhNjkyYTlmNzUwLTEwMzE2NTctMjAyNS0wNC0yMy1lbg==/tiny/Organovo-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDRhNjEyZjctMmI3Yi00M2NjLTkyZDEtYzBhNjkyYTlmNzUwLTEwMzE2NTctMjAyNS0wNC0yMy1lbg==/tiny/Organovo-Inc-.png"/></p>

Organovo控股

VIVS

<p>Organovo 控股（Nasdaq: ONVO）将于 2025 年 4 月 24 日更名为 VivoSim Labs, Inc.，其普通股将在纳斯达克资本市场以新股票代码 “VIVS” 交易。现有股东无需对此变更采取任何行动。公司的 CUSIP 号码将保持不变。文中包含前瞻性声明，提醒谨慎对待这些声明</p>

<p>04/23/2025 - 08:05 AM</p>
<div class="lb-trans"><p>2025 年 4 月 23 日- 上午 8:05</p>
</div><p>SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc.</p>
<div class="lb-trans"><p>圣地亚哥，2025 年 4 月 23 日（GLOBE NEWSWIRE）-- Organovo Holdings, Inc.（纳斯达克：ONVO）（“公司”）宣布将继续推进其 3D 生物打印和传统技术，作为 VivoSim Labs, Inc.。</p>
</div><p>A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company’s common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol “VIVS” at market open on April 24, 2025.</p>
<div class="lb-trans"><p>公司名称变更为 VivoSim Labs, Inc.将于 2025 年 4 月 24 日生效，公司普通股将于 2025 年 4 月 24 日市场开盘时在纳斯达克资本市场以新股票代码 “VIVS” 开始交易。</p>
</div><p>No action is required by existing stockholders with respect to the name and ticker symbol change. The Company’s common stock will continue to be listed on the Nasdaq Capital Market and the CUSIP number assigned to the Company's common stock (68620A302) will remain unchanged.</p>
<div class="lb-trans"><p>现有股东无需对名称和股票代码的变更采取任何行动。公司的普通股将继续在纳斯达克资本市场上市，分配给公司普通股的 CUSIP 号码（68620A302）将保持不变。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p><em>Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with theSEC, including its Annual Report on Form 10-K filed with theSEConMay 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with theSEConFebruary 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws oftheUnited States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.</em></p>
<div class="lb-trans"><p><em>本新闻稿中包含的任何不描述历史事实的声明构成前瞻性声明，符合 1995 年《私人证券诉讼改革法》的定义。此处包含的任何前瞻性声明均基于当前预期，但受到多种风险和不确定性的影响。这些风险和不确定性以及其他因素在公司向 SEC 提交的文件中有更详细的说明，包括其于 2024 年 5 月 31 日提交的 10-K 表格年度报告，以及其于 2025 年 2 月 19 日提交的最新季度报告 10-Q 表格中更新的风险因素。您不应对这些前瞻性声明过度依赖，这些声明仅在作出之日有效。这些警示声明应与公司未来可能发布的任何书面或口头前瞻性声明一起考虑。除非适用法律要求，包括美国的证券法，公司不打算更新任何前瞻性声明，以使这些声明与实际结果、后续事件或情况相符，或反映意外事件的发生。</em></p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>IR@organovo.com</p>
<div class="lb-trans"><p>IR@organovo.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRek56QTVPU00yT1RBd01ERTNJekl3TWpBd09EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTQzNzA5OSM2OTAwMDE3IzIwMjAwODU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDRhNjEyZjctMmI3Yi00M2NjLTkyZDEtYzBhNjkyYTlmNzUwLTEwMzE2NTctMjAyNS0wNC0yMy1lbg==/tiny/Organovo-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MDRhNjEyZjctMmI3Yi00M2NjLTkyZDEtYzBhNjkyYTlmNzUwLTEwMzE2NTctMjAyNS0wNC0yMy1lbg==/tiny/Organovo-Inc-.png"/></p>

VivoSim 将继续推动 Organovo 的 3D 生物打印技术 | Organovo 控股股票新闻